Advanced searches left 3/3

Prostate Cancer - Crossref

Summarized by Plex Scholar
Last Updated: 24 April 2022

* If you want to update the article please login/register

Clinical and Biochemical Outcomes of High-Risk Prostate Cancer Patients treated with Third Generation Prostate Cryosurgery

Objects: To publish results after modern-day primary prostate cryosurgery in D Amico's high-risk localised prostate cancer patients treated at a large academic center. 730 cases of total gland prostate CS were investigated, with 80 men with high risk disease identifying themselves. Six of the 39 men with BCR had metastatic disease on bone scan; 19 of 34 men with BCR under BCR underwent anti-androgen therapy, 18 of whom had also received neoadjuvant hormonal therapy. Conclusions: Prostate CS is a controversial drug for high-risk patients, and our early research revealed low cancer-specific mortality and morbidity in these high-risk patients, leading to improved biochemical and local control rates for these high-risk patients. These high-risk patients require prostate CS, and we therefore recommend that further investigation of CS for high-risk disease is required.

Source link: https://doi.org/10.6000/1927-7229.2013.02.02.10


Metabolic Alterations, Vascular Disease and Advanced Prostate Cancer: New Players for Metastatic Advanced Prostate Cancer?

Introduction: Epidemiologic studies have attributed a metabolic imbalance in prostate cancer aggressiveness, but no definitive consensus has been reached. Methods: A retrospective review of 66 patients with advanced PCa diagnosis between 2005 and 2009 was carried out. In 25 patients with advanced PCa and bone metastases compared to 41 patients with advanced non-metastatic PCa, we investigated hypertension, hypercholesterolemia, and cardiovascular disease. The results:Hypertension was strongly related to advanced PCa with bone metastases, according to researchers. Hypercholesterolemia was also strongly associated with aggressive metastatic PCa. Metastatic PCa and vascular disease have been shown to have a significant relationship.

Source link: https://doi.org/10.6000/1927-7229.2014.03.01.5


Prostate Cancer Treatment on the Basis of an Individual Risk Profile; Can we Reduce Overtreatment?

Prostate cancer is the most common cancer in male populations with an incidence rate of 93 per 100. 000 men in Europe, and the sixth leading cause of cancer-related deaths in men. Because of advancement in diagnosis and/or widespread screening techniques, prostate cancer mortality rates have been reduced. However, in clinical practice, men with a potentially lethal disease-threatening cancer are often treated specifically, resulting in unnecessary suffering from severe side effects coinciding with active treatment. For patients with low-risk PCa, the actual diagnosis could be postponed or even skipped, and second, radical therapy could be postponed or entirely avoided. A prostate cancer nomogram has been created to help identify the presence of a prostate cancer nomogram. These multivariate prediction tools can be of help in avoiding unnecessary biopsies, reducing overdiagnosis, or identifying potentially indolent prostate cancer following diagnosis, and consequently adjust the treatment regimen.

Source link: https://doi.org/10.6000/1927-7229.2013.02.01.2


Biological and Pathological Study of Prostate Cancer at Localized Stage in Western Algeria

Methodology: This review focused on 160 patients aged 50 to 80 years, with histologically confirmed prostate cancer adenocarcinoma and research in urology hospitals in western Algeria between 2007 and 2011. At an early stage, the difference between 5-6 in 5 patients with TPSA 10 ng / ml was unclear, with a score of 7 out of ten patients with TPSA between 10-20 ng / ml at an apoorically differentiated stage, and finally a score of 8 in 20 patients with TPSA between 10-20 ng / ml at an apoorly differentiated stage to a score of 8 in 20 patients with a t ml at a ml despite a / ml at /ml at / ml at ml at / ml at a / ml at / /ml at / a / ml at /ml at /ml at / /ml at / /ml at /.

Source link: https://doi.org/10.6000/1927-7229.2013.02.02.7


T1a/T1b transitional zone prostate cancer detection rates in patients who had TURP for clinically diagnosed benign prostatic enlargement in Southern Nigeria

Incidental findings of prostate cancer in the TURP specimen for the clinically diagnosed benign disease may have occurred. If more than 5% of the resected chips are malignant, the American Joint Committee on Cancer TNM staging of prostate cancer allocates T1a if they are malignant, and T1b if more than 5% are malignant. Aim: To determine the prevalence of incidental prostate cancer in TURP specimens of patients with medically diagnosed benign prostatic enlargement. Methodology: This was a retrospective review of patients who had TURP for clinically diagnosed BPE or biopsy-diagnosed BPH for a period of 8 years from January 2013 to December 2020. Patients with incomplete information and patients with transrectal peripheral zone prostate biopsy confirmed cancers before TURP were excluded from the study. Conclusion: The Incidental T1a/T1b transitional zone adenocarcinoma detection rate in TURP specimens in the investigation was 13. 6%.

Source link: https://doi.org/10.47672/ejhs.995


An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer

Prostate-specific membrane antigens are an excellent target for prostate cancer diagnosis and treatment. Prolonging the half-life of PSMA probes has been deemed as an effective way to enhance tumor detection. We've posted a 64Cu-labeled PSMA tracer conjugating with maleimidopropionic acid, 64Cu-PSMA-CM, which demonstrated an excellent capability to detect PSMA-overexpressing tumors in a postponed time. Cell culture in PSMA-positive 22Rv1 cells, human serum albumin binding affinity, and micro-PET imaging studies in a 22Rv1 model were conducted to determine albumin binding capacity and PSMA specificity. 64Cu-PSMA-CM in 22Rv1 cells increased over time, and it could bind to HSA with a high protein binding ratio. These findings revealed that 64Cu-PSMA-CM was PSMA-specific with a higher tumor uptake, indicating that MPA is an alternate option for raising the radioactivity content in PSMA-expressing tumors and developing the ligands for PSMA radioligand therapy.

Source link: https://doi.org/10.3390/ph15050513


Differential In Vitro Growth and Cell Killing of Cancer versus Benign Prostate Cells by Oncolytic Parainfluenza Virus

The development of effective oncolytic viruses will require knowing the difference between viruses replication and killing between normal and cancer cells. Here, we have investigated prostate cell lines of metastatic cancer and benign non-tumorigenic prostate cells lines infected with a mutation-influenza virus 5 encoding a missing V protein and a hyperfusogenic F protein. These results reveal that IFN-I sensitivity is a key determinant of P/V/F propagation among populations of cancer versus benign cells, and that, in addition, differences in the expression of apoptotic pathways and syncytia development can influence variability in cancer and benign cells.

Source link: https://doi.org/10.3390/pathogens11050493


External validation of the Candiolo nomogram for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy: a retrospective cohort study

Abstract This paper was designed to reclassify high-risk prostate cancer patients treated with carbon-ion radiotherapy and androgen deprivation therapy using the Candiolo nomogram and assess usefulness to predict the following 10-year biochemical recurrence. According to the Candiolo nomogram, six hundred seventy-two high-risk prostate cancer patients were reclassified. In addition, five predictors of the Candiolo nomogram in our patients were evaluated by the Fine and Gray regression hazards model. The Candiolo nomogram will help identify our high-risk prostate cancer patients treated with carbon-ion radiotherapy and androgen deprivation therapy as well as evaluate the biochemical recurrence delicately.

Source link: https://doi.org/10.1093/jjco/hyac066


Causes of Death after Prostate Cancer Diagnosis: A Population-Based Study

It's unclear if noncancer causes in prostate cancer patients are responsible for prostate cancer. Patients with PCa had a higher risk of death from any noncancer cause within five years, in particular other infectious diseases and suicide, and self-inflicted injury. Patients with or without chemotherapy within 1 to 5 years after diagnosis, pneumonia and influenza, nephrotic syndrome, and atherosclerosis are all at risk of death from COPD, pneumonia and influenza, nephrosis, and atherosclerosis in patients with or without radiotherapy or chemotherapy, with or without radiotherapy or chemotherapy. In addition, the risk of death from noncancer causes has gradually decreased in all patients with PCa during each follow-up period after diagnosis.

Source link: https://doi.org/10.1155/2022/8145173


Self-Assembled PSMA-Targeted Nanoparticles Enhanced Photodynamic Therapy in Prostate Cancer

Prostate cancer plays a significant role in human life. To minimize the side effects of prostate cancer therapy, we created a functionalized Progen-Chlorin e6 NPs herein. We developed a functionalized PSMA-Ce6 by coupling the hydrophobic photosensitizer Ce6 with the small hydrophilic molecule PSMA ligand. The molecularly targeted PSMA inhibitor is not limited to blocking PSMA but also increase the accumulation of the photosensitizer Ce6 in the tumor and result in complete tumor ablation under near-infrared irradiation.

Source link: https://doi.org/10.1155/2022/8726662

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions